KR20160147709A - 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 - Google Patents

4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 Download PDF

Info

Publication number
KR20160147709A
KR20160147709A KR1020167023761A KR20167023761A KR20160147709A KR 20160147709 A KR20160147709 A KR 20160147709A KR 1020167023761 A KR1020167023761 A KR 1020167023761A KR 20167023761 A KR20167023761 A KR 20167023761A KR 20160147709 A KR20160147709 A KR 20160147709A
Authority
KR
South Korea
Prior art keywords
adh2
aldh2
subject
ethanol
alcohol dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167023761A
Other languages
English (en)
Korean (ko)
Inventor
토마스 이 데일리
엘리자베스 씨 스콰이어스
킨훙 페오니 유
Original Assignee
랩터 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랩터 세라퓨틱스 인크. filed Critical 랩터 세라퓨틱스 인크.
Publication of KR20160147709A publication Critical patent/KR20160147709A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y10S514/867—
    • Y10S514/872—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020167023761A 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 Ceased KR20160147709A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18588409P 2009-06-10 2009-06-10
US61/185,884 2009-06-10
PCT/US2010/037879 WO2010144518A1 (en) 2009-06-10 2010-06-09 Genotype specific methods for treating human subjects using 4- methylpyrazole

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029368A Division KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Publications (1)

Publication Number Publication Date
KR20160147709A true KR20160147709A (ko) 2016-12-23

Family

ID=43309203

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147029368A Ceased KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
KR1020167023761A Ceased KR20160147709A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
KR1020127000590A Ceased KR20120032523A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020147029368A Ceased KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127000590A Ceased KR20120032523A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Country Status (13)

Country Link
US (4) US20120252857A1 (enExample)
EP (2) EP2440049B1 (enExample)
JP (2) JP5836270B2 (enExample)
KR (3) KR20140138318A (enExample)
CN (2) CN106943398A (enExample)
AU (1) AU2010258821B2 (enExample)
DK (1) DK2440049T3 (enExample)
ES (1) ES2656489T3 (enExample)
NO (1) NO2440049T3 (enExample)
PT (1) PT2440049T (enExample)
SG (1) SG176734A1 (enExample)
TW (1) TWI523653B (enExample)
WO (1) WO2010144518A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117701A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and drug composition containing novel aldehyde dehydrogenase for suppressing tremor or movement disorder
WO2024117699A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Novel aldehyde dehydrogenase food and drug composition for improving behavior and motor function
WO2024117698A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and pharmaceutical composition for detoxifying endogenous aldehydes

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
JP6421249B2 (ja) * 2015-10-26 2018-11-07 株式会社日立製作所 デバッグを支援する方法及び計算機システム
WO2019209123A1 (en) * 2018-04-27 2019-10-31 Remedius Biotech Limited Diagnosis, risk reduction and treatment of conditions associated with elevated aldehyde levels
CN109381458B (zh) * 2018-12-16 2020-09-01 李志武 甲吡唑及其盐在制备抗癫痫药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106620A (en) 1980-12-22 1982-07-02 Takara Shuzo Co Ltd Ameliorant for alcoholic metabolism
GB0404481D0 (en) 2004-02-28 2004-03-31 Rhodia Cons Spec Ltd Soap control agent
TW200534852A (en) * 2004-03-03 2005-11-01 Convivia 4-methylpyrazole formulations for inhibiting ethanol intolerance
WO2009058874A1 (en) * 2007-11-02 2009-05-07 Monte Woodow C Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117701A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and drug composition containing novel aldehyde dehydrogenase for suppressing tremor or movement disorder
WO2024117699A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Novel aldehyde dehydrogenase food and drug composition for improving behavior and motor function
WO2024117698A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and pharmaceutical composition for detoxifying endogenous aldehydes

Also Published As

Publication number Publication date
JP5836270B2 (ja) 2015-12-24
US20180098964A1 (en) 2018-04-12
DK2440049T3 (en) 2018-02-19
EP3311811A1 (en) 2018-04-25
JP2015155422A (ja) 2015-08-27
TWI523653B (zh) 2016-03-01
AU2010258821B2 (en) 2016-03-10
US20120322843A1 (en) 2012-12-20
ES2656489T3 (es) 2018-02-27
SG176734A1 (en) 2012-01-30
JP2012529526A (ja) 2012-11-22
CN102458121A (zh) 2012-05-16
KR20140138318A (ko) 2014-12-03
WO2010144518A1 (en) 2010-12-16
US20120252857A1 (en) 2012-10-04
NO2440049T3 (enExample) 2018-05-12
CN106943398A (zh) 2017-07-14
TW201110966A (en) 2011-04-01
EP2440049B1 (en) 2017-12-13
EP2440049A1 (en) 2012-04-18
PT2440049T (pt) 2018-03-05
US20170007578A1 (en) 2017-01-12
KR20120032523A (ko) 2012-04-05
EP2440049A4 (en) 2012-12-05
AU2010258821A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US20230348981A1 (en) Methods and compositions for inhibiting and treating neurological conditions
US20170007578A1 (en) Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole
EP4005570B1 (en) Pridopidine for use in treating rett syndrome
US20090192166A1 (en) Method for augmenting the effects of serotonin reuptake inhibitors
AU2021380758A1 (en) Novel rna transcript
US20200316028A1 (en) Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US20180179594A1 (en) Multiple system atrophy and the treatment thereof
US11807907B2 (en) Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
HK1168993B (en) Genotype specific methods for treating human subjects using 4-methylpyrazole
HK1168993A (en) Genotype specific methods for treating human subjects using 4-methylpyrazole
US20240409928A1 (en) Novel rna transcript
US20240068035A1 (en) Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
Gu et al. Emerging perspectives on precision therapy for Parkinson's
HK40009961B (en) Use of pridopidine for treating rett syndrome

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160829

Application number text: 1020147029368

Filing date: 20141020

PA0201 Request for examination
PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170214

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170919

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170919

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170614

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170109

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180115

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171219

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170919

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170614

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170214

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170109